Journal of Clinical Oncology
Articles in this Issue
Serum HER2 level as a predictor of treatment efficacy and prognosis in advanced breast cancer patients treated with trastuzumab deruxtecan (T-DXd).
1039 Background: No validated liquid biopsy biomarker currently exists to predict the efficacy of trastuzumab deruxtecan (...
Validation of a generative AI-based clinical decision support system for surgical extent in thyroid cancer in Brazil: Potential aid to de-escalating treatment to preserve function.
1604 Background: The decision between thyroid lobectomy (TL) and total thyroidectomy (TT) for differentiated thyroid carci...
Evaluation of the cytostatic properties of berberine derivatives on a cell culture of acute T-cell lymphoblastic leukemia (Jurkat).
e19114 Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that accounts for...
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.
e17109 Background: Enzalutamide (enza) monotherapy is a treatment option for BCR. Although EMBARK allowed dose interruptio...
Critical survivorship challenges among breast cancer survivors in a low- and middle-income country: A tertiary cancer center experience from Southern India.
e24136 Background: With improving breast cancer survival, long-term survivorship care needs are increasing steadily. Data...
Prevalence and financial burden of WHO-defined disability among childhood cancer survivors: A report from the St. Jude Lifetime Cohort study (SJLIFE).
12114 Background: Survivors of childhood cancer are at high risk for chronic health conditions that may result in disabili...
Assessing cervical cancer screening awareness and community-identified barriers to prevention in Peoria, Tazewell, and Woodford Counties, Illinois.
e22509 Background: Cervical cancer is largely preventable through routine screening and human papillomavirus (HPV) vaccina...
Phase II study of utidelone plus fruquintinib for the treatment of platinum-resistant recurrent ovarian cancer (FRUTD trial).
5579 Background: Patients (pts) with platinum-resistant ovarian cancer (PROC) have a poor prognosis, and traditional cytot...
Phase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ.
4036 Background: First-line therapy for HER2-negative advanced GC/GEJ remains a huge unmet clinical need. Claudin 18.2 (CL...
Are socio-economic status indicators barriers for enrollment in phase 1 clinical trials?
1652 Background: Socio-economic Status (SES) indicators create barriers to access Phase 1 clinical trial (Ph1) enrollment,...
Consolidation PD-(L)1 inhibitor after definitive chemoradiotherapy for unresectable stage III NSCLC: Systematic review and meta-analysis of randomized controlled trials.
e20054 Background: Consolidation immune checkpoint inhibition after definitive chemoradiotherapy (CRT) improves outcomes i...
Progression-free survival outcomes of first-line maintenance therapy in ovarian cancer stratified by <i>BRCA</i> and homologous recombination status: A multi-center real-world analysis.
e17596 Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are widely used in ovarian cancer; however, real-world d...
CheckMate-9DW 4-year follow-up: Overall survival by depth of response and outcomes in long-term survivors.
4104 Background: Nivolumab plus ipilimumab (NIVO + IPI) was globally approved as a first-line (1L) treatment for unresecta...
Longitudinal changes in coping among early phase cancer clinical trial (EPCT) participants.
11035 Background: EPCT participants use varying strategies to cope with uncertainty related to their cancer, treatment, an...
Neoadjuvant versus adjuvant chemotherapy in cardiac tumor resection: A propensity-matched analysis of perioperative and long-term outcomes.
11555 Background: Optimal timing of systemic therapy for primary cardiac malignancies is undefined. We compared outcomes a...
MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET/AGO-B-062; NCT05559411).
TPS652 Background: In the last decades, the proportion of breast cancer patients receiving breast-conserving surgery has i...
TrioMBM: A multicenter, phase II trial of relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases.
TPS9604 Background: Melanoma brain metastases (MBM) are a leading cause of morbidity and mortality for patients (pts) with...
Machine learning modeling for predicting 60-day prognosis in newly diagnosed advanced solid tumors.
1622 Background: Accurate mid-term prognosis estimation in patients newly diagnosed with advanced, non-operable or metasta...
Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.
7520 Background: Daratumumab (Dara) requires CD16-expressing natural killer (NK) cells for anti-myeloma activity. The use...
Transplant-associated thrombotic microangiopathy after hematopoietic stem cell transplantation in adults: Incidence and inpatient outcomes in the U.S. National Inpatient Sample, 2016-2022.
e18570 Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is one of the severe and fatal under recognis...
Incidence and risk factors for pneumonitis in patients with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: A retrospective cohort study.
e16600 Background: Enfortumab vedotin plus pembrolizumab (EV+P) is first line standard of care for locally advanced or met...
Temporal trends in incidence and mortality in biliary tract cancers in the United States, 2000–2023: A SEER-based analysis.
e16153 Background: Biliary tract cancers (BTCs) are aggressive malignancies with an increasing global burden. In the Unite...
Cancer screening in the transgender population: Examining the specificities of cancer risk from a health equity perspective—An analytical cross-sectional study.
e22545 Background: The transgender population faces significant structural and social barriers to healthcare access. In on...
Durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma: A window of opportunity trial (DORA).
TPS4268 Background: Resectable pancreatic ductal adenocarcinoma (PDAC) comprises < 20% of cases and remains associated...
Tumor-naïve multimodal cfDNA MRD assay to predict recurrence in a prospective cohort of patients undergoing curative-intent lung cancer resection.
8016 Background: Tumor-informed circulating tumor DNA (ctDNA) assays can achieve high sensitivity for minimal residual dis...